Study of Pembrolizumab Maintenance Following First-Line Platinum Based Chemotherapy in Patients With Metastatic Squamous - Non-Small Cell Lung Cancer (sNSCLC)

PHASE2

Phase

TERMINATED

Status

Enrollment

OTHER

Sponsor class

Stopped Since trial start in Jan. 2016 only 41 patients could be recruited until planned date of end of follow up period. Under consideration of this fact the recruitment of the planned 130 patients was not possible within a reasonable recruitment period.

Conditions

Metastatic Squamous Non-small Cell Lung Cancer

Interventions

DRUG: Pembrolizumab
DRUG: Placebo

Sponsor

AIO-Studien-gGmbH

Collaborators

[object Object]